TABLE 1.
Association between antipsychotic and side effect gene expression profiles
| Amisulpride | Risperidone | Volinanserin | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Side effect | NCBI GEO Series | Array | Case/ control | Negative score (n) | Positive score (n) | P | Negative score (n) | Positive score (n) | P | Negative score (n) | Positive score (n) | P |
| Atherosc‐lerosis | GSE23746 |
Sentrix humanref ‐8 expression beadchip |
Control (n) Case (n) |
16 35 |
2 38 |
.002 |
16 30 |
1 43 |
6.98 × 10−5 |
15 37 |
2 38 |
5.5 × 10−3 |
| VTE | GSE19151 |
Affymetrix human ‐ genome U133A 2.0 |
Control (n) Case (n) |
‐ ‐ |
‐ ‐ |
‐ |
30 17 |
5 36 |
8.13 × 10−7 |
39 28 |
17 39 |
.002 |
| Influenza | GSE17156 |
Affymetrix human ‐ genome U133A 2.0 |
Control (n) Case (n) |
8 1 |
2 10 |
.002 |
0 2 |
1 6 |
1 |
7 2 |
2 10 |
.009 |
| Bone density | GSE2208 |
Affymetrix ‐ human genome U133A |
Control (n) Case (n) |
6 2 |
1 4 |
.103 |
6 2 |
1 6 |
0.041 |
7 2 |
1 6 |
.041 |
| CAD | GSE7638 |
Affymetrix human ‐ genome U133A 2.0 |
Control (n) Case (n) |
18 27 |
19 51 |
.159 |
18 22 |
18 44 |
0.137 |
22 32 |
19 60 |
.056 |
| Bone density | GSE13850 |
Affymetrix ‐ human genome U133A |
Control (n) Case (n) |
9 11 |
8 7 |
.738 |
9 11 |
8 6 |
0.728 |
10 13 |
10 7 |
.523 |
| Rhinovirus | GSE17156 |
Affymetrix human ‐ genome U133A 2.0 |
Control (n) Case (n) |
0 1 |
10 5 |
.375 |
4 0 |
2 0 |
1 |
2 2 |
14 13 |
1 |
| Respiratory‐ syncytial virus | GSE17156 |
Affymetrix human ‐ genome U133A 2.0 |
Control (n) Case (n) |
16 12 |
2 5 |
.228 |
9 3 |
0 1 |
.308 |
16 14 |
4 3 |
1 |
Abbreviations: CAD, coronary artery disease; NCBI GEO, National Center for Biotechnology Information Gene Expression Omnibus; VTE, venous thromboembolism.
Notes: Raw P values of Fisher exact test on 2 × 2 table are shown, statistically significant values after Bonferroni correction (0.05/8 = 0.00625) are highlighted in bold.
‘‐’ denotes test not done as no individual VTE samples were correlated with amisulpride in the high throughput screen stage.
'Positive score: the number of individual samples in each NCBI GEO series with a positive score for each antipsychotic.
'Negative score: the number of individual samples in each NCBI GEO series with a negative score for each antipsychotic.
"Case/control": the case/control status of each sample in each NCBI GEO series